The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study

Elizabeth Schneider, Elizabeth Martin, Pia Rotshtein, Kasim L Qureshi, Samuel R Chamberlain, Maartje S Spetter, Colin T Dourish, Suzanne Higgs

Research output: Contribution to journalArticlepeer-review

89 Downloads (Pure)

Abstract

Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.

Original languageEnglish
Article number9
Pages (from-to)8
JournalTranslational Psychiatry
Volume12
Issue number1
DOIs
Publication statusPublished - 10 Jan 2022

Bibliographical note

Funding Information:
Role of Funding Source. Funding for this work was provided by BBSRC Grant UK to SH grant number: BB/N008847/1. The BBSRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Colin T Dourish is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. Prof. Chamberlain’s role in this study was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z & 110049/Z/15/A). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Prof. Chamberlain receives honoraria from Elsevier for editorial work. He previously consulted for Promentis.

Publisher Copyright:
© 2021, The Author(s).

Keywords

  • Attention Deficit Disorder with Hyperactivity
  • Binge-Eating Disorder
  • Biomedical Research
  • Central Nervous System Stimulants
  • Cognition
  • Dextroamphetamine
  • Double-Blind Method
  • Feeding Behavior
  • Female
  • Humans
  • Lisdexamfetamine Dimesylate
  • Reward
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study'. Together they form a unique fingerprint.

Cite this